Metabolic agents such as GLP-1 receptor agonists led to modest TG reductions (≈20–25%) but to a significant improvement in hepatic fat content (−30–35%) and resolved steatosis in up to one-third of patients (Figure 1). This evidence concerns the gene GLP1R and steatosis.